11 tasks to receive funding to sustain the Commonwealth’s aggressive edge in advancing human health and connecting communities throughout Massachusetts to the innovation financial system
Waltham – At this time, the Baker-Polito Administration and the Massachusetts Life Sciences Middle (MLSC) announced $30.95 million in capital grant funding to support the state’s international leadership in the life sciences sector. In complete, 11 tasks throughout Massachusetts will obtain funding by way of the MLSC’s Aggressive Capital Program to support advances in human health, speed up innovation in the areas of medical and translational research, and broaden the capability of life sciences improvement and job progress across the Commonwealth.
“Our administration is dedicated to generating economic growth and supplying researchers with the tools they need to create new advancements in improving patient outcomes,” stated Governor Charlie Baker. “By investing in the Massachusetts innovation economy, we can work together with academic and industry partners to support game-changing technological research and create jobs across the state.”
“This capital funding further enhances our world-class talent pipeline, spurring additional educational and career opportunities throughout every region of the Commonwealth,” stated Lieutenant Governor Karyn Polito. “Our administration is pleased to make investments in educational and training programming to ensure that any resident pursuing a career in the life sciences can thrive, positioning Massachusetts to continue to lead the way in this field.”
The MLSC’s Competitive Capital Program invests capital dollars by way of a competitive course of in excessive potential financial improvement tasks that promise to make a big contribution to the state’s life sciences ecosystem. Moreover, the competitive program goals to tackle funding gaps in capital dollars, industry support, and federal funding for instructional establishments, incubators, analysis institutions, and workforce coaching packages, whereas additionally catalyzing personal and philanthropic funding to match state investment and getting ready the life sciences workforce of the longer term.
“These investments represent new opportunities for our life sciences ecosystem to support job growth, talent development, and entrepreneurial growth across the Commonwealth,” stated MLSC President and CEO Travis McCready. “By continuing to expand regional access in education and hands-on training and supporting innovative, novel technologies, we are unlocking new potential in our understanding of human physiology to push toward medical advances for patients around the world.”
Leaders representing the awardee establishments shared how this funding will positively influence their work:
“We are grateful to the Massachusetts Life Sciences Center for their generous support. The Center for Translation Neurotrauma Imaging (CTNI) will spur high-tech job and industry growth, train the next generation research leaders and further consolidate the Commonwealth of Massachusetts as a global leader in life science innovation,” stated Karen Antman, MD, provost, Boston College Medical Campus and dean, Faculty of Drugs.
“Mass Life Sciences Center’s support is helping the Massachusetts General Hospital explore new ways to transform clinical research in the neurosciences by providing the infrastructure to construct a new unit that will allow us to learn more from clinical research in neurological and psychiatric diseases including Alzheimer’s disease,” says Bradley Hyman, MD, PhD, director of the Mass. Alzheimer Illness Research Middle at MGH. “We plan a state of the art unit that combines recent advances in clinical trial technologies, advances in neuroimaging with MGH’s Martinos Center, and biomarker discovery all in a facility that will allow early phase clinical trials to proceed efficiently, gathering all the data together to facilitate learnings. We are really grateful for the opportunity to grow this program, with the hope that we will translate these opportunities into future therapies for dementia and other diseases.”
“We are honored to receive this award, which will allow BATL to expand into training on biomanufacturing” stated Dr. Jared Auclair, the director of Northeastern’s BATL and precept investigator and the lead researcher for the grant proposal. “This will allow BATL to provide end-to-end training on biologics and grow the field in Massachusetts.”
“GMGI/GBA is thrilled to be able to add a state-of-the-art cell culture room to our facility,” stated GMGI Board Chair Michele Might. “It will enable us to expand our program offerings and comprehensively train our students to meet the needs of the area’s life sciences companies.”
“This support will expand Baystate Health’s capacity to perform efficient and compliant clinical trials, speed medical advances, and make novel treatments available to our diverse patient populations,” stated Dr. Peter Friedmann, Chief Research Officer for Baystate Health and Affiliate Dean for Analysis, University of Massachusetts Medical Faculty-Baystate. “We are grateful to MLSC, our legislators, the Governor and the citizens of the Commonwealth for this investment in the future of biomedical research in Western Massachusetts.”
“There is a real need in the industry for both qualified professionals graduating from programs like Quincy College’s Biotechnology and GMP program, and for customized incumbent worker training that we offer in our state-of-the-art biotechnology labs at Quincy College. This specialized and customized training pipeline supports the Commonwealth’s biopharma industry form the ground up. Quincy College is uniquely positioned to support skill development for all levels of professionals working in the Biotech industry. Quincy College excels at addressing this real-world need head-on, providing a resource for continuing education as incumbent worker training and critical skill development for those just entering the biotechnology industry. With the generous Massachusetts Life Science Consortium Grant, the Quincy College Biotechnology and Compliance program will be able to further the study of biotechnology and good manufacturing practice and implement ongoing positives changes initiated by the Quincy College leadership to make the College not only a wonderful work place but also a modern institution that provides the best possible education for students and workforce training for workers throughout the Commonwealth,” stated Quincy School President Michael G. Bellotti.
“The research planned going forward with the establishment of this new resource at Brigham and Women’s Hospital will further expand the potential for benefiting our patients with precision therapy. The siting of the new resource, between the Harvard Medical School quadrangle and the Brigham, at the heart of the Longwood Medical Area, will surely inspire new programs to leverage unique intellectual and physical resources from different institutions to bring together programs that promise to become much more than the sum of each of their investments and contributions.” Paul J. Anderson, MD, PhD, Chief Educational Officer and Senior Vice-President of Analysis at the Brigham.
“We are so proud of the success of our MBI companies,” stated Massachusetts Biomedical Initiatives (MBI) President & CEO Jon Weaver. “It’s truly amazing to witness the caliber of life and health science companies that are choosing to make their start in Central Massachusetts. Our partnership with the Massachusetts Life Science Center will provide additional opportunities for these startups to seed, scale, and succeed in Central Massachusetts, and accommodate the high demand for laboratory space.”
“We are excited about the opportunity to create a Center for Therapeutics and Genomics Training at MassBay,” stated MassBay President Dr. David Podell. “And we are extremely grateful to Mass Life Sciences for their support for this important initiative which will allow us to better prepare underrepresented students for careers in the life sciences.”
“We appreciate MLSC’s continued support and commitment in supporting NSIV to deliver on its mission to support and nurture early-stage life science companies in Boston North,” stated North Shore InnoVentures CEO Chris Ilsley. “The commitment will allow us to not only support more companies currently here in Massachusetts, and continue to make us relevant in Boston North’s Life Science community; and will also attract and support international life science companies looking to make Massachusetts their home for the North American market.”
That is the sixth spherical of the aggressive capital program administered by the MLSC. Candidates are educational organizations, research establishments, analysis hospitals, business incubators and other non-profit organizations. The MLSC recognizes that investment in capital tasks and infrastructure is important to create and maintain the attributes that make Massachusetts engaging to innovation sectors reminiscent of life sciences. So far, the MLSC has awarded or committed greater than $455 million to support capital tasks throughout the state.
The MLSC’s infrastructure investments have contributed to the creation of more than 1.9 million sq. ft of latest life sciences analysis and manufacturing area across the Commonwealth, whereas creating more than 5,800 jobs in the building trades and in the life sciences sector. The greater than $30 million in capital funds in this most up-to-date round of the aggressive program might be distributed across 11 totally different tasks, including six research establishments, three tasks centered on workforce improvement efforts, and two incubators in Worcester and Beverly. Most of the tasks are multi-partnered and leverage a further $29.85 million in investments by companion institutions or the awardees themselves.
This previous June, Governor Baker signed An Act offering continued funding in the life sciences industry in the Commonwealth to invest up to $623 million in bond authorization and tax credits over 5 years in schooling, research and improvement and workforce coaching. This laws will serve to reinforce the Baker-Polito Administration’s commitment to making certain Massachusetts’ management in the life sciences sector.
MLSC Competitive Capital Program award descriptions:
Baystate Medical Middle – $3,949,912
The capital undertaking will broaden capacity to carry out medical trials in Western Massachusetts by constructing a medical trials unit at Baystate Medical Middle in Springfield and a satellite tv for pc unit at Baystate Franklin Medical Middle in Greenfield, and enhancing coaching in medical research in collaboration with area people schools. This venture will speed up human testing of progressive digital health, biopharma, and medical units developed in the Commonwealth. Furthermore, for Baystate and its companions in Western Massachusetts, the undertaking will improve entry to revolutionary remedies for the patients and communities inside the region, broaden collaborations with educational and industry companions, and develop a workforce expert in medical analysis.
Boston Youngsters’s Hospital – $1,545,050
The MLSC’s funding will support the launch of a multi-disciplinary initiative at Boston Youngsters’s Hospital targeted on advances in precision drugs in the remedy of cardiac illness. The Middle for Accelerated Therapeutic Improvement (CAT-D) will deliver an interdisciplinary workforce of cardiac biologists, bioengineers, and clinicians together underneath one roof to develop progressive human cell and tissue models of human illness. CAT-D will speed up therapeutic improvement via using disease-relevant, human in vitro models, enabling “clinical trials in a dish” to determine patient teams most certainly to respond to specific therapies or most at risk for antagonistic responses. The initiative may even function a collaborative hub for scientists in academia and biotechnology, seeding academic-industry partnerships and accelerating translation of primary discoveries. An initial focus of CAT-D will probably be inherited heart illness, however the same infrastructure and rules are equally applicable to different uncommon and inherited illnesses.
Boston University Medical Faculty – $4,991,000
The Middle for Translation Neurotrauma Imaging at Boston College Medical Faculty will set up a begin‐of‐the‐art research facility to speed up improvement of transformative brain imaging methods, purposes, protocols, and markers to detect and monitor delicate modifications in the brain that end result from neurotrauma and improve danger for neurodegenerative illnesses resembling persistent traumatic encephalopathy (CTE) and Alzheimer’s disease. Any such imaging know-how will fill an present hole in detecting and tracking earlier than rising remedies could be successfully examined and deployed in people.
Brigham and Ladies’s Hospital – $5,000,000
Brigham and Ladies’s Hospital will use MSLC funding to advance the rigor and effectivity of medical trials and biomedical research with focused therapeutics by offering info otherwise not out there to drug corporations, as well as enhancing primary research at Massachusetts educational establishments. The MLSC-funded instrument package deal will provide a singular resource in america by combining quantitative metabolomics and high-resolution spatial mass spectrometry imaging, including a high-resolution 15 Tesla mass spectrometer. This novel, state-of- the-art facility, which might be made out there to the scientific group and biotechnology corporations, will purpose to transcend cancer analysis and accelerate the event of latest medicines for infectious disease, cardiac drugs, and neurological illness states, together with Alzheimer’s and Parkinson’s illness.
Gloucester Marine Genomics Institute – $174,383
The Gloucester Marine Genomics Institute (GMGI) will receive $174,383 to construct out and equip a new, state-of-the-art cell tradition laboratory. The lab will improve scholar experience and training at GMGI’s Gloucester Biotechnology Academy, whereas additionally addressing an industry want for entry-level technicians with cell culturing expertise and advance its genomics research objectives. This funding builds upon earlier MLSC support for the construction of the world-class genomics research institute on Cape Ann, made potential by a previous $2.7 million MLSC capital grant.
Massachusetts Biomedical Initiatives – $3,494,256
Massachusetts Biomedical Initiatives (MBI), one of the first life sciences incubators in the Commonwealth, is at present residence to more than 30 life sciences corporations, having “graduated” one other 95 corporations, which employ roughly 825 individuals in the native life sciences cluster in central Massachusetts. With the support of the MLSC, MBI will redevelop 17 Briden Road within Worcester’s Gateway Park by establishing further incubator area, which can embrace a “Stage II” incubator. MBI will function more than 20,000 square ft of a renovated facility to increase its enterprise incubation operations, together with 19 further suites and supporting workplace area. Moreover, the inclusion of a “Stage II” incubator will present MBI the power to create 5-7 suites of around 1,000- three,000 square ft for rising corporations. This area will function a bridge for these corporations to grow and maintain their business fashions and stop the monetary and logistical stress that can trigger corporations to wrestle and fail, by leaving the incubator setting before they’re ready.
Massachusetts Common Hospital – $four,805,000
MLSC investment will support the launch of a “Big Data & Digital Health Hub”, administered by the Medical and Translational Analysis Unit (CTRU) at Massachusetts Common Hospital. The CTRU is concentrated on dramatically reworking medical analysis to speed up progress in the prevention, management and remedy of complicated brain issues like Alzheimer’s illness, Parkinson’s illness, temper and nervousness issues. The MLSC’s funding will support the acquisition of a high-end computing system for evaluation of numerous datasets and a knowledge visualization room with a hyperwall (video wall that uses coordinated visualizations for interactive exploration of multidimensional knowledge and knowledge simulation) and digital actuality functionality. Additionally, funding will support superior multi-sensor medical examination rooms, wearable and remote digital units for affected person monitoring, and dedicated mass spectrometry for large-scale measurements. This initiative will enable unprecedented analysis of individualized precision drugs knowledge on mind well being with an ultimate objective of creating new therapies.
MassBay Group School – $500,000
MLSC funding might be used to create a Middle for Therapeutics and Genomics Coaching at MassBay Group School that goals to rework group school technical schooling by getting ready underrepresented college students for employment and analysis positions in the Massachusetts life sciences ecosystem. The school will improve its biotechnology amenities, permitting for the development of an array of latest, credit score and non‐credit score, courses in areas resembling genomics, developmental biology, and biomanufacturing. In addition, MassBay Group School will present laboratory area via summer time programming for highschool students, in addition to, to small businesses for worker coaching.
North Shore InnoVentures – $1,650,000
Since 2012, North Shore InnoVentures (NSIV) and Endicott School have cast a profitable partnership to ship on the mission to foster and support regional life science startups. In the present day this collaboration continues as NSIV will now manage the expanding Endicott School incubator area to higher support the growing number and range of life sciences startups lively in the North Shore region of the state. MLSC funding will broaden infrastructure capacity at NSIV and acquire key instrumentation for each the NSIV and Endicott amenities that may function a catalyst for startups’ product improvement and facilitate coaching of a highly expert workforce for the life sciences industry. The advanced instrumentation at NSIV and Endicott School shall be used by startups, scholar interns from the region’s high faculties, group school, and four-year schools, in addition to, corporations across Massachusetts more broadly. The economic impression of this challenge will embrace: serving to to create and fill high-quality life-sciences jobs in Massachusetts; higher getting ready the workforce for those jobs; and affording early-stage life sciences corporations in the region access to tools and providers to improve their potential for progress and success.
Northeastern University – $four,271,867
Northeastern University will make the most of MLSC funding to set up a training program in biomanufacturing analysis and quality control, by providing hands-on coaching in state-of-the-art amenities at its Burlington campus. The college plans to construct out two further laboratories: a mock GMP suite and a biomanufacturing suite, in addition to, purchasing training gear, including a producing scale bioreactor and purification system for the biomanufacturing suite, and instrumentation upgrades to the campus’ mass spectrometry laboratory.
Quincy School – $725,000
MLSC funding will enable Quincy School to proceed its management in providing comprehensive workforce training and schooling in manufacturing. The school’s bio manufacturing certificates and affiliate diploma packages have been at capacity enrollment persistently for the past seven years. Quincy School will utilize funding to upgrade present gear and enhance the scholar expertise. This new funding will build upon $645,000 in earlier MLSC funding to support Quincy School’s biotechnology and GMP (Good Manufacturing Apply) programming.
Concerning the Massachusetts Life Sciences Middle
The Massachusetts Life Sciences Middle (MLSC) is an economic improvement funding company devoted to supporting the growth and improvement of the life sciences in Massachusetts, residence to probably the most verdant and productive life sciences ecosystem in the world. Via public-private funding initiatives, the MLSC helps innovation, analysis and improvement, commercialization, and manufacturing activities in the fields of biopharma, medical gadget, diagnostics and digital well being. Since its creation in 2007, the MLSC has strategically deployed over $700 million in Massachusetts, by way of a mixture of grants, loans, capital infrastructure investments, tax incentives and workforce packages. These investments have created hundreds of jobs and propelled the event of latest therapies, units and scientific developments which might be enhancing affected person well being and well-being in Massachusetts and beyond.